Cancer Res Treat.  2024 Oct;56(4):1240-1251. 10.4143/crt.2023.977.

Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma

Affiliations
  • 1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 3Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Brain Korea 21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Abstract

Purpose
Clinical outcomes of surgery after neoadjuvant chemotherapy have not been investigated for locally advanced pancreatic cancer (LAPC), despite well-established outcomes in borderline resectable pancreatic cancer (BRPC). This study aimed to investigate the clinical outcomes of patients with LAPC who underwent curative resection following neoadjuvant chemotherapy.
Materials and Methods
We retrospectively reviewed the records of patients diagnosed with pancreatic adenocarcinoma between January 2017 and December 2020.
Results
Among 1,358 patients, 260 underwent surgery following neoadjuvant chemotherapy. Among 356 LAPC patients, 98 (27.5%) and 147 (35.1%) of 418 BRPC patients underwent surgery after neoadjuvant chemotherapy. Compared to resectable pancreatic cancer (resectable PC) with upfront surgery, both LAPC and BRPC exhibited higher rates of venous resection (28.6% vs. 49.0% vs. 4.0%), arterial resection (30.6% vs. 6.8% vs. 0.5%) and greater estimated blood loss (260.5 vs. 213.1 vs. 70.4 mL). However, hospital stay, readmission rates, and postoperative pancreatic fistula rates (grade B or C) did not differ significantly between LAPC, BRPC, and resectable PC. Overall and relapse-free survival did not differ significantly between LAPC and BRPC patients. The median overall survival was 37.3 months for LAPC and 37.0 months for BRPC. The median relapse-free survival was 22.7 months for LAPC and 26.0 months for BRPC.
Conclusion
Overall survival time and postoperative complications in LAPC patients who underwent curative resection following neoadjuvant chemotherapy showed similar results to those of BRPC patients. Further research is needed to identify specific sub-populations of LAPC patients who benefit most from conversion surgery and to minimize postoperative complications.

Keyword

Pancreatic neoplasms; Neoadjuvant therapy; Locally advanced pancreatic cancer; Borderline resectable pancreatic cancer

Figure

  • Fig. 1. Patient selection flow chart. NACT, neoadjuvant chemotherapy; PDAC, pancreatic ductal adenocarcinoma.

  • Fig. 2. The overall survival (OS) curves were compared between locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC). The median OS of LAPC patients who underwent surgery after neoadjuvant chemotherapy (NACT) was 37.3 months (95% confidence interval [CI], 32.4 to 42.2) and the median OS of BRPC patients who underwent surgery after NACT was 37.0 months (95% CI, 32.6 to 41.3).

  • Fig. 3. The relapse-free survival (RFS) curves were compared between locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC). The median RFS of LAPC patients who underwent surgery after neoadjuvant chemotherapy (NACT) was 22.7 months (95% confidence interval [CI], 17.9 to 27.5) and the median RFS of BRPC patients who underwent surgery after NACT was 26.0 months (95% CI, 21.7 to 30.3).

  • Fig. 4. This figure shows the survival curves of patients who underwent upfront surgery with resectable pancreatic cancer (PC). It includes overall survival (OS) and recurrence-free survival (RFS) curves. The median OS of resectable pancreatic cancer was 38.4 months (95% confidence interval [CI], 36.6 to 40.2) and the median RFS of resectable pancreatic cancer was 32.3 months (95% CI, 30.2 to 34.4).

  • Fig. 5. The overall survival curves were compared between locally advanced pancreatic cancer patients who underwent surgery after neoadjuvant chemotherapy (NACT) and those who received only chemotherapy without surgery, among those confirmed to have partial response (PR) and stable disease (SD). Overall survival was re-defined as the time from chemotherapy initiation to death from any cause in this analysis The median overall survival time for patients who underwent surgery after NACT was 43.2 months (95% confidence interval [CI], 38.4 to 48.1 months), while the median overall survival time for patients who received only chemotherapy was 21.5 months (95% CI, 19.7 to 23.3 months).


Reference

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–49.
Article
2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020; 159:335–49.
Article
3. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24:4846–61.
Article
4. Mohammed S, Van Buren G 2nd, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014; 20:9354–60.
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7–33.
Article
6. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021; 326:851–62.
7. Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016; 12:1929–46.
Article
8. Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J. 2017; 23:333–42.
Article
9. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16:1727–33.
Article
10. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021; 19:439–57.
11. Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020; 4:6–13.
Article
12. Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, et al. Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol. 2015; 22:3618–24.
Article
13. Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today. 2019; 49:894–906.
Article
14. Amano R, Kimura K, Nakata B, Yamazoe S, Motomura H, Yamamoto A, et al. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer. Surgery. 2015; 158:191–200.
Article
15. Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann Surg Oncol. 2015; 22 Suppl 3:S1212–20.
Article
16. Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016; 264:457–63.
17. Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022; 40:1220–30.
Article
18. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817–25.
Article
19. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691–703.
Article
20. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015; 44:515–21.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228–47.
Article
22. Clavien PA, Strasberg SM. Severity grading of surgical complications. Ann Surg. 2009; 250:197–8.
Article
23. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161:584–91.
24. McCullough TC, Roth JV, Ginsberg PC, Harkaway RC. Estimated blood loss underestimates calculated blood loss during radical retropubic prostatectomy. Urol Int. 2004; 72:13–6.
Article
25. Vidri RJ, Olsen WT, Clark DE, Fitzgerald TL. Upfront resection versus neoadjuvant therapy for T1/T2 pancreatic cancer. HPB (Oxford). 2021; 23:279–89.
Article
26. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021; 273:341–9.
Article
27. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014; 155:977–88.
Article
28. Belfiori G, Fiorentini G, Tamburrino D, Partelli S, Pagnanelli M, Gasparini G, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021; 169:403–10.
Article
29. Pecorelli N, Pagnanelli M, Cinelli L, Di Salvo F, Partelli S, Crippa S, et al. Postoperative outcomes and functional recovery after preoperative combination Cchemotherapy for pancreatic cancer: a propensity score-matched study. Front Oncol. 2019; 9:1299.
30. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990; 66:56–61.
Article
31. Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005; 23:7529–35.
Article
32. Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer-“the good, the bad, and the ugly” candidates for surgery? J Gastrointest Oncol. 2021; 12:2450–60.
Article
33. Saito T, Ishido K, Kudo D, Kimura N, Wakiya T, Nakayama Y, et al. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Mol Clin Oncol. 2017; 6:963–7.
Article
34. Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013; 20:590–600.
Article
35. Wang M, Zhu P, Chen Z, Yang L. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer? Anticancer Drugs. 2022; 33:e686–91.
Article
36. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403–13.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr